PL4048278T3 - Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu - Google Patents

Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu

Info

Publication number
PL4048278T3
PL4048278T3 PL20807558.0T PL20807558T PL4048278T3 PL 4048278 T3 PL4048278 T3 PL 4048278T3 PL 20807558 T PL20807558 T PL 20807558T PL 4048278 T3 PL4048278 T3 PL 4048278T3
Authority
PL
Poland
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
benz
dione
Prior art date
Application number
PL20807558.0T
Other languages
English (en)
Inventor
Maria Soraya Carrancio ANTON
Tonia J. Buchholz
Shailaja Kasibhatla
Antonia Lopez-Girona
Rama Krishna Narla
Michael POURDEHNAD
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of PL4048278T3 publication Critical patent/PL4048278T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20807558.0T 2019-10-21 2020-10-20 Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu PL4048278T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924028P 2019-10-21 2019-10-21
PCT/US2020/056408 WO2021080935A1 (en) 2019-10-21 2020-10-20 Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
PL4048278T3 true PL4048278T3 (pl) 2024-03-18

Family

ID=73449175

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20807558.0T PL4048278T3 (pl) 2019-10-21 2020-10-20 Sposoby leczenia złośliwych nowotworów hematologicznych z zastosowaniem 2-(2,6-dioksopiperydyn-3-ylo)-4-((2-fluoro-4-((3- morfolinoazetydyn-1-ylo)metylo)benzylo)amino)izoindolino-1,3-dionu

Country Status (21)

Country Link
US (2) US11666579B2 (pl)
EP (1) EP4048278B1 (pl)
JP (1) JP2022552882A (pl)
KR (1) KR20220103722A (pl)
CN (2) CN115087448A (pl)
AU (1) AU2020372330A1 (pl)
BR (1) BR112022007417A2 (pl)
CA (1) CA3154504A1 (pl)
DK (1) DK4048278T3 (pl)
ES (1) ES2967929T3 (pl)
FI (1) FI4048278T3 (pl)
HR (1) HRP20231487T1 (pl)
HU (1) HUE064768T2 (pl)
IL (1) IL292266A (pl)
LT (1) LT4048278T (pl)
MX (1) MX2022004683A (pl)
PL (1) PL4048278T3 (pl)
PT (1) PT4048278T (pl)
RS (1) RS64936B1 (pl)
SI (1) SI4048278T1 (pl)
WO (1) WO2021080935A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4048278T3 (fi) * 2019-10-21 2023-12-19 Celgene Corp Menetelmiä hematologisten syöpien hoitamiseksi 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dionia käyttämällä

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566290B (zh) * 2014-10-30 2020-05-22 康朴生物医药技术(上海)有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
RS64663B1 (sr) 2018-04-23 2023-11-30 Celgene Corp Supstituisana jedinjenja 4-aminoizoindolin-1,3-diona i njihova upotreba u lečenju limfoma
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
FI4048278T3 (fi) * 2019-10-21 2023-12-19 Celgene Corp Menetelmiä hematologisten syöpien hoitamiseksi 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dionia käyttämällä

Also Published As

Publication number Publication date
CN115087448A (zh) 2022-09-20
CN115919871A (zh) 2023-04-07
AU2020372330A1 (en) 2022-05-19
WO2021080935A1 (en) 2021-04-29
PT4048278T (pt) 2024-01-12
EP4048278A1 (en) 2022-08-31
ES2967929T3 (es) 2024-05-06
EP4048278B1 (en) 2023-11-01
RS64936B1 (sr) 2024-01-31
FI4048278T3 (fi) 2023-12-19
US11666579B2 (en) 2023-06-06
BR112022007417A2 (pt) 2022-07-12
SI4048278T1 (sl) 2024-01-31
HRP20231487T1 (hr) 2024-03-01
HUE064768T2 (hu) 2024-04-28
KR20220103722A (ko) 2022-07-22
US20210113577A1 (en) 2021-04-22
JP2022552882A (ja) 2022-12-20
IL292266A (en) 2022-06-01
LT4048278T (lt) 2023-12-11
MX2022004683A (es) 2022-05-10
DK4048278T3 (da) 2024-01-08
US20230277548A1 (en) 2023-09-07
CA3154504A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL287145A (en) Methods for treating non-Hondkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 , 3-dione
EP4048668A4 (en) METHODS OF TREATING HEMATOLOGICAL CANCER AND USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL) BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
HUE046008T2 (hu) I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
EP3796909A4 (en) TREATMENT OF MULTIPLE MYELoma AND USE OF BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)-PIPERAZINE -1-YL)-3-FLUOROBENZONITRILE
RS64029B1 (sr) Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida
RS62541B1 (sr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezana jedinjenja kao prs inhibitori za tretman npr. raka
IL280052A (en) Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia
MX2018007147A (es) Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion.
IL292266A (en) Methods for the treatment of hematological malignancy using -(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1.3-dione)
PH12020500211A1 (en) Methods of treating behavior alterations
IL284509A (en) Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide
IL284680A (en) Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same
PL3658547T3 (pl) Sposób wytwarzania n-(5-(4-(4-formylo-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-yloamino)-4-metoksy-2-morfolinofenylo)akrylamidu
IL284665A (en) Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same
IL307942A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione
IL292265A (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion
ES2571078A1 (es) Deslizadera para ascensores y ascensor que comprende dicha deslizadera